Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225923 · ClinicalTrials.gov registry record · Phase 2
A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
A Phase 2 study of Cytomegalovirus Disease, sponsored by Nobelpharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT04225923 is a Phase 2 study of Cytomegalovirus Disease that has completed, run by Nobelpharma. The registered enrollment target is 87 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04225923, a Phase 2 study of Cytomegalovirus Disease, has completed, sponsored by Nobelpharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to assess the efficacy and safety of NPC-21 when administered prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney transplant from a CMV seropositive donor.
Conditions Studied
Interventions
- DRUG NPC-21 Low dose
- DRUG NPC-21 High dose
- DRUG NPC-21 Placebo
Study Locations (20)
Ohio
- The Christ Hospital - Cincinnati
- University of Cincinnati College of Medicine - Cincinnati
- Cleveland Clinic - Cleveland
Aichi-ken
- Research site_204 - Nagakute
- Research site_201 - Nagoya
- Research site_202 - Toyoake
Georgia
- Piedmont Healthcare - Atlanta
- Augusta University Medical Center - Augusta
Texas
- Renal Disease Research Institute - Dallas
- University of Texas Southwestern - Dallas
Hyōgo
- Research site_206 - Kobe
- Research site_205 - Nishinomiya
Arizona
- Mayo Clinic - Scottsdale - Phoenix
California
- California Institute of Renal Research - La Mesa
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2023-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225923
The ClinicalTrials.gov registry entry for NCT04225923 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nobelpharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytomegalovirus Disease appearing as the primary indexed condition, and to 3 interventions - of which NPC-21 Low dose is the first listed.
NCT04225923 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Ohio, Aichi-ken, Georgia.
Frequently Asked Questions
What is clinical trial NCT04225923 about?
NCT04225923 is a clinical study titled "A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection". The primary objective is to assess the efficacy and safety of NPC-21 when administered prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney transplant from a CMV seropositive donor.
What is the current status of trial NCT04225923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2020-06-01. Estimated completion is 2023-02-08.
What conditions does trial NCT04225923 study?
This clinical trial studies the following conditions: Cytomegalovirus Disease.
What interventions are being tested in trial NCT04225923?
The interventions under investigation include: NPC-21 Low dose (DRUG), NPC-21 High dose (DRUG), NPC-21 Placebo (DRUG).
Who is sponsoring clinical trial NCT04225923?
This trial is sponsored by Nobelpharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04225923 being conducted?
This trial has 20 study locations across Arizona, California, Georgia, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.